Sartorius stock holds at EUR 188 as analysts see upside

Sartorius (ISIN DE0006292006) stock is trading at EUR 188.00 per share as of August 17, 2026, according to a recent quote overview that lists this level as the last closing price on the Tradegate venue.

The same market data set shows the last close on another listing at EUR 233.90, highlighting how different trading venues can exhibit price dispersion even for the same underlying company.

For investors, the EUR 188.00 level now sits below the average analyst target price of EUR 265.95, indicating that the consensus view still sees upside potential relative to current trading.

Valuation, consensus and recent performance

A detailed consensus page compiled on August 18, 2026 reports an average target price of EUR 265.95 for Sartorius shares, with the most recent last close flagged at EUR 233.90 on Tradegate as of August 17, 2026.

This comparison means the average target stands EUR 32.05 above the Tradegate close, a spread that underscores the gap between current pricing and where analysts expect the stock to trade over the medium term.

The same overview indicates that the Tradegate quotation at EUR 188.00 reflects a 1.16 percent decline over the last five days, while the year-to-date performance is marginally lower by 0.31 percent as of August 18, 2026.

A separate market snapshot focusing on another venue shows Sartorius stock quoted at EUR 183.60, down 1.92 percent on the day, with a reference level of EUR 185.20 in after-hours trading that is 0.87 percent higher than the regular-session close as of August 18, 2026.

Taken together, these figures suggest that the stock has been moving in a relatively narrow band, with modest short-term declines offset by an only slightly negative performance since the start of 2026.

From a valuation standpoint, the distance between the current EUR 188.00 price and the EUR 265.95 average target price implies a potential upside of more than 40 percent if consensus expectations were fully realized.

Analyst stance and sector context

The broker-research overview for Sartorius updated on August 18, 2026 lists a separate reference price of EUR 176.20, with the change over the past five days and since the start of the year both shown at 0.00 percent and -9.03 percent, respectively.

This combination of a flat five-day movement and a more clearly negative year-to-date figure points to a period in which the share price had weakened earlier in 2026 before stabilizing in recent sessions.

Analyst opinions compiled in the same source reflect a mix of ratings that, when taken together, are consistent with the presence of a positive target-price gap and a cautious stance shaped by the prior downside.

In sector-comparison data dated August 18, 2026, Sartorius is shown with the EUR 183.60 quote and the -1.92 percent daily move, measured against its own previous level of EUR 185.20 that closed 0.87 percent higher in after-hours trading.

This sector lens indicates that, while Sartorius has experienced some short-term volatility, the movements remain within a range typical for highly valued life-science tools and bioprocessing companies exposed to cyclical investment in biopharmaceutical capacity.

For investors following the European life-sciences segment, the fact that Sartorius stock still trades below both its EUR 233.90 Tradegate close reference and the EUR 265.95 consensus target may make the valuation narrative a central consideration.

Bioprocessing solutions as growth engine

Sartorius is a leading supplier of bioprocessing equipment and consumables used in the development and manufacture of biopharmaceuticals, including biologic drugs and vaccines.

The company’s portfolio spans single-use bioreactors, filtration systems, chromatography solutions, and analytics tools that help customers scale up cell culture processes efficiently and reproducibly.

One representative product line is its range of single-use bioreactors, which enable drug developers and manufacturers to run upstream processing with flexible, disposable components instead of fixed stainless-steel systems.

These systems are designed to simplify cleaning validation, reduce contamination risks, and shorten changeover times between batches, which can be particularly valuable when facilities handle multiple products or clinical projects.

Beyond hardware, Sartorius also provides integrated software solutions that monitor critical process parameters and support data-driven optimization of yields and quality attributes.

Because many of these offerings are embedded directly into customers’ manufacturing workflows, recurring revenue from consumables and services can become a key driver of the company’s long-term growth profile.

Sartorius stock and current market level

As of August 17, 2026, Sartorius stock most recently closed at EUR 188.00 on one of its European trading venues, while other market references show levels such as EUR 183.60 and EUR 233.90 across different listings updated through August 18, 2026.

Against the background of an average analyst target price of EUR 265.95, these figures indicate that the stock currently trades well below the consensus fair-value estimate, with recent performance metrics pointing to modest short-term declines and only slightly negative year-to-date returns.

Fact box

Company: Sartorius AG

ISIN: DE0006292006

Ticker: SRT

Exchange: Xetra

Price (as of August 17, 2026, close): EUR 188.00

Sector / Industry: Life sciences tools and bioprocessing

Index membership: MDAX